CAMBIUM BIO LIMITED — Capital/Financing Update 2020

Aug 27, 2020

==> picture [160 x 33] intentionally omitted <==

ASX Announcement

28 August 2020

Regeneus receives payment from Progenza OA Kyocera deal

Highlights:

• Regeneus receives payment of 100M JPY (~A$1.3M) from Kyocera Corporation

• • Payment follows the completion of execution of the agreement between the two companies for Kyocera to exclusively develop and commercialise Regeneus’ lead stem cell platform technology Progenza for the treatment of Knee Osteoarthritis in Japan

Regeneus Ltd (ASX: RGS) ( Regeneus or the Company ), a clinical-stage regenerative medicine company, is pleased to announce that is has received a payment of 100M JPY (~A$1.3M) from Kyocera Corporation (Kyocera, TYO:6971) following the completion of execution of the agreement between the two companies for Kyocera to exclusively develop and commercialise Regeneus’ lead stem cell platform technology Progenza for the treatment of Knee Osteoarthritis in Japan (refer to ASX announcement on 11 August).

Pursuant with the terms of the agreement, Regeneus is expected to receive a further US$4M from Kyocera in October 2020. The Company will notify the market once this payment has been received.

-ENDS-

About Regeneus

Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies to address unmet medical needs in human health markets with a focus on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza and Sygenus. Visit www.regeneus.com.au for more information.

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Regeneus Ltd

Investor and Media Contact

WE Communications T: 02 9237 2805 E: WE-AURegeneus@we-worldwide.com

2 Paddington Street, Paddington, NSW 2021 Ph: +61 2 9499 8010 • www.regeneus.com.au • ABN 13 127 035 358